While prior research has shed light on the impact of RB1 inactivation on prostate cancer progression and lineage plasticity, there still remains a critical need to comprehensively understand the underlying mechanisms and identify therapeutic vulnerabilities in RB1-deficient CRPC. This evidence concerns the gene RB1 and prostate carcinoma.